The Current Evidence on Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
The Korean Journal of Thoracic and Cardiovascular Surgery
; : 160-167, 2020.
Article
| WPRIM
| ID: wpr-835274
Biblioteca responsável:
WPRO
ABSTRACT
Surgical resection is the mainstay of treatment for locally advanced esophageal cancer.Neoadjuvant therapy is recommended to improve survival, based on the results of severalrandomized trials and meta-analyses. However, controversy remains regarding howto combine surgery, radiotherapy, and chemotherapy. Moreover, in East Asia, the predominanthistological type is esophageal squamous cell carcinoma, which has a differentepidemiology and tumor biology from esophageal or gastroesophageal junctional adenocarcinoma.As such, the management of esophageal cancer in East Asia seems to bedifferent from that in Western countries. Thus, this article reviews the current evidence onneoadjuvant therapy and considers the optimal combinations and ongoing strategies ofmultimodal therapy for esophageal squamous cell carcinoma.
Texto completo:
1
Índice:
WPRIM
Revista:
The Korean Journal of Thoracic and Cardiovascular Surgery
Ano de publicação:
2020
Tipo de documento:
Article